4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $664,264 | +4.8% | 52,181 | +48.8% | 0.00% | 0.0% |
| Q2 2023 | $633,625 | +123.9% | 35,065 | +113.0% | 0.00% | +100.0% |
| Q1 2023 | $282,947 | -4.2% | 16,460 | +23.8% | 0.00% | 0.0% |
| Q4 2022 | $295,393 | -32.9% | 13,300 | -75.7% | 0.00% | 0.0% |
| Q3 2022 | $440,000 | +136.6% | 54,736 | +104.9% | 0.00% | – |
| Q2 2022 | $186,000 | -66.9% | 26,711 | -28.2% | 0.00% | -100.0% |
| Q1 2022 | $562,000 | -20.2% | 37,200 | +15.9% | 0.00% | 0.0% |
| Q4 2021 | $704,000 | +104.1% | 32,100 | +150.8% | 0.00% | 0.0% |
| Q3 2021 | $345,000 | +62.7% | 12,800 | +45.7% | 0.00% | – |
| Q2 2021 | $212,000 | – | 8,786 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |